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OBJECTIVE — Obesity is associated with increased metabolic and cardiovascular risk. The
ectopic fat hypothesis suggests that subcutaneous fat may be protective, but this theory has yet
to be fully explored.
RESEARCH DESIGN AND METHODS — Participants from the Framingham Heart
Study (n  3,001, 48.5% women) were stratiﬁed by visceral adipose tissue (VAT) into sex-
speciﬁc tertiles. Within these tertiles, age-adjusted abdominal subcutaneous adipose tissue
(SAT) tertiles were examined in relation to cardiometabolic risk factors.
RESULTS — InthelowestVATtertile,riskfactorprevalencewaslow,althoughsystolicblood
pressure in women and rates of high triglycerides, impaired fasting glucose, hypertension, and
the metabolic syndrome in men increased with increasing SAT tertile (all P  0.04). In contrast,
inthetopVATtertile,lowertriglycerideswereobservedinmenwithincreasingSAT(64.4%high
triglycerides in SAT tertile 1 vs. 52.7% in SAT tertile 3, P  0.03). Similar observations were
made for women, although results were not statistically signiﬁcant (50.6% high triglycerides in
SAT tertile 1 vs. 41.0% in tertile 3, P  0.10). Results in the highest VAT tertile were notable for
a lack of increase in the prevalence of low HDL in men and women and in rates of impaired
fastingglucoseinmenwithincreasingsubcutaneousfat,despitesizabledifferencesinBMIacross
SAT tertiles (27.1 to 36.3 kg/m
2 [women]; 28.1 to 35.7 kg/m
2 [men]).
CONCLUSIONS — Although adiposity increases the absolute risk of metabolic and cardio-
vascular disease, abdominal subcutaneous fat is not associated with a linear increase in the
prevalence of all risk factors among the obese, most notably, high triglycerides.
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O
besityisassociatedwithmultiplecar-
diometabolic risk factors, including
insulin resistance (1), diabetes (2),
hypertension (3), and dyslipidemia (4).
Variations in fat distribution may mediate
such risks, with visceral adipose tissue
(VAT) associated with more adverse risk
factorproﬁlesthanabdominalsubcutane-
ous adipose tissue (SAT) (5,6). The ec-
topic fat hypothesis proposes that obesity
represents a failure of adipocyte growth
and differentiation, resulting in “acquired
lipodystrophy”andfatdepositioninliver,
skeletal muscle, and pancreatic -cells
(7). Such ectopic fat stores are hypothe-
sized to contribute to the pathogenesis of
impaired insulin secretion and insulin re-
sistance and to mediate obesity-related
cardiovascular disease (8).
In addition to the detrimental effects
of VAT, human and animal studies have
suggested a possible protective role for
subcutaneous fat. In humans, increased
subcutaneouslegfatisassociatedwithde-
creased risk of disturbed glucose metabo-
lism and dyslipidemia, independent of
abdominal fat (9). Thiazolidinedione
treatment, which increases total fat mass,
mostly in subcutaneous fat stores, im-
provesinsulinsensitivity(10).Removalof
VATbyomentectomyresultsindecreased
glucose and insulin levels in humans,
(11), whereas removal of SAT by liposuc-
tion does not always result in improve-
ments in glucose metabolism or lipid
levels (12,13). Transplantation of subcu-
taneous fat into visceral compartments in
mice produces decreases in body weight
and total fat mass and improved glucose
metabolism, suggesting that subcutane-
ous fat may be intrinsically different from
visceral fat in ways that are beneﬁcial
(14).
Therefore, the purpose of the present
study was to test the hypothesis that ab-
dominal subcutaneous fat is a protective
fat depot in terms of cardiometabolic risk
factor prevalence. We theorized that
among those with similar levels of VAT,
increasing SAT might be associated with
decreases in cardiometabolic risk factor
prevalencedespiteincreasingBMIandto-
tal abdominal fat.
RESEARCH DESIGN AND
METHODS— The Framingham Heart
Study is a prospective cohort study that
beganin1948.In1971,theoffspringand
spouses of the original cohort were en-
rolledintheOffspringStudy,andin2002
the children of the original cohort’s off-
spring were enrolled in the Third Gener-
ationStudy.BetweenJune2002andApril
2005, 3,529 Offspring and Third Gener-
ation participants underwent chest and
abdominal computed tomographic (CT)
scanning in conjunction with the Multi-
Detector Computed Tomography
(MDCT) substudy. The present study
sample consisted of the 3,001 partici-
pants (1,455 women and 1,546 men)
who had interpretable CT scans (both
chest and abdominal), who were free of
cardiovascular disease, and who had
complete covariate information.
The institutional review boards of the
Boston University Medical Center and
Massachusetts General Hospital ap-
proved the study protocol. All subjects
provided informed written consent.
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and volumetric measurements
Participantsunderwenteight-sliceMDCT
abdominal scanning in a supine position
(LightSpeed Ultra, General Electric, Mil-
waukee, WI). Twenty-ﬁve contiguous
5-mm thick slices (120 kVp, 400 mA,
gantry rotation time 500 ms, and table
feed 3:1) were obtained, covering 125
mm above the level of S1.
VAT and SAT volumes were quanti-
ﬁed from CT scans using a dedicated off-
line workstation (Aquarius 3D
Workstation; TeraRecon, San Mateo, CA)
using a semiautomatic segmentation
technique. A reader manually traced the
abdominal muscular wall separating the
two layers. An image display window
width of 195 to 45 Hounsﬁeld units
andawindowcenterof120Hounsﬁeld
units were used to identify pixels con-
taining fat. VAT was deﬁned as adipose
tissue inside the abdominal muscular
wall and SAT as adipose tissue outside
the abdominal muscular wall. Interclass
correlations for inter-reader compari-
sons were 0.997 for SAT and 0.992 for
VAT on a random sample of 100 scans;
high intra-reader correlations were sim-
ilarly obtained.
Risk factor and covariate assessment
Covariates were measured at the seventh
Framingham Offspring examination
(1998–2001) and the ﬁrst Third Genera-
tion examination (2002–2005). BMI was
calculated as weight in kilograms divided
by the square of height in meters. Waist
circumferencewasmeasuredattheumbi-
licus. Serum triglycerides, total and HDL
cholesterol, and fasting plasma glucose
were measured in fasting morning sam-
ples obtained from attendees. Diabetes
was deﬁned as fasting plasma glucose
126 mg/dl or treatment with a hypogly-
cemic agent or insulin; impaired fasting
glucose was deﬁned as a fasting plasma
glucose level of 100–125 mg/dl in the ab-
sence of diabetes treatment. Hyperten-
sion was deﬁned as systolic blood
pressure 140 mmHg and diastolic
blood pressure as 90 mmHg or antihy-
pertensive treatment. High triglycerides
weredeﬁnedas150mg/dlorlipidtreat-
ment. Low HDL was deﬁned as 40
mg/dl for men or 50 mg/dl for women.
Current smoking was deﬁned as smoking
1 cigarette per day in the past year. Al-
cohol use was evaluated through a physi-
cian-administered questionnaire and
categorizedasmoreorlessthan14drinks
per week (men) or 7 drinks per week
(women). Women were classiﬁed as
postmenopausal if periods had stopped
for 1 year. Metabolic syndrome was
deﬁned by modiﬁed Adult Treatment
Panel III criteria (impaired fasting glu-
cose deﬁned as fasting plasma glucose
100–125 mg/dl in the absence of treat-
ment of diabetes, the high triglyceride
component was deﬁned as triglycer-
ides150mg/dlortreatmentwithalip-
id-lowering agent, and blood pressure
criteria were modiﬁed to include treat-
ment for hypertension).
Statistical analysis
Study participants were stratiﬁed by VAT
into sex-speciﬁc tertiles. Within each ter-
tile,subjectswerecategorizedfurtherinto
sex-speciﬁc abdominal SAT tertiles. Age-
adjusted means and prevalences of risk
factors including BMI, waist circumfer-
ence, fasting glucose, diabetes, HDL cho-
lesterol, triglycerides, hypertension, and
the metabolic syndrome were compared
across the SAT tertiles. Because overall
and visceral adiposity increases with age,
all analyses were age-adjusted. As a sec-
ondary analysis, participants were sepa-
rately stratiﬁed into SAT tertiles within
each clinical BMI category (normal
weight, overweight, and obese), and the
analyses were repeated. All analyses were
performed using SAS (version 9.1); two-
tailed values of P  0.05 were considered
signiﬁcant.
RESULTS
Study sample characteristics
Overall, 1,455 women (mean age 51.4
years) and 1,546 men (mean age 48.6
years) comprised the study sample. The
average BMI was 26.7 kg/m
2 for women
and 28.3 kg/m
2 for men, with 24.1% of
women and 27.3% of men classiﬁed as
obese. Approximately one-quarter of
women had high triglycerides, low HDL,
hypertension, and the metabolic syn-
drome, whereas 41.1% of men had high
triglycerides, 31.1% had low HDL, 28.5%
had hypertension, and 35.2% had the met-
abolic syndrome. Additional study sample
characteristics are listed in Table 1.
Age-adjusted tertile analysis
All measures of adiposity (BMI, waist cir-
cumference, SAT, and VAT) increased
signiﬁcantly for women and men across
SATtertileswithineachVATtertile(Table
2).AmongthoseinthelowestVATtertile,
risk factor prevalence was uniformly low
and increased with increasing SAT tertile
(Table 3). Among women, the age-
adjusted linear trend was signiﬁcant for
systolic blood pressure (109 mmHg in
SAT tertile 1 vs. 114 mmHg in SAT tertile
Table 1—Study sample characteristics
Women Men
n 1,455 1,546
Age (years) 51.4  9.5 48.6  10.1
BMI (kg/m
2) 26.7  5.4 28.3  4.4
Waist circumference (cm) 92.0  14.4 100.3  11.5
Systolic blood pressure (mmHg) 119.5  17.4 123.1  14.3
Diastolic blood pressure (mmHg) 73.5  9.1 78.5  8.9
Fasting plasma glucose (mg/dl) 94.9  16.6 101.0  20.0
Triglycerides (mg/dl) 109.8  65.2 139.6  102.9
Impaired fasting glucose* 251 (18.0) 558 (38.5)
Diabetes 62 (4.3) 95 (6.2)
High triglycerides† 354 (24.3) 635 (41.1)
Low HDL‡ 352 (24.2) 481 (31.1)
Hypertension 352 (24.2) 440 (28.5)
Metabolic syndrome 361 (24.8) 543 (35.2)
Current smoking 178 (12.2) 203 (13.1)
Alcohol (14 drinks/week in men/7
drinks/week in women) 222 (15.3) 247 (16.0)
Postmenopausal 694 (47.7) —
Hormone replacement therapy 333 (22.9) —
SAT (cm
3) 3,076  1,449 2,599  1,185
VAT (cm
3) 1,309  809 2,158  967
DataaremeansSDorn(%).*Deﬁnedasfastingplasmaglucose100–125mg/dlintheabsenceofdiabetes
treatment. †Deﬁned as triglycerides 150 mg/dl or lipid treatment. ‡Deﬁned as HDL 40 mg/dl (men) or
50 mg/dl (women).
Porter and Associates
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weresigniﬁcantforseveralriskfactors.Of
particular note are the signiﬁcant in-
creases in prevalence rates of impaired
fasting glucose (19.1% in SAT tertile 1 vs.
29.1% in SAT tertile 3, P  0.03) and
high triglycerides (12.1% in SAT tertile 1
vs. 20.4% in SAT tertile 3, P  0.04).
In the middle (second) VAT tertile,
risk factor prevalence was generally
higherthanthatinVATtertile1andagain
displayedapatternofincreaseacrossSAT
tertiles. Among women, linear trends
were signiﬁcant for systolic blood pres-
sure (117 mmHg in SAT tertile 1 vs. 122
mmHg in SAT tertile 3, P  0.01) and the
metabolic syndrome (8.3% in SAT tertile
1 vs. 27.2% in SAT tertile 3, P  0.0001).
Among men, linear trends were also sig-
niﬁcant and increasing for the metabolic
syndrome (22.5% in SAT tertile 1 vs.
50.7% in SAT tertile 3, P  0.0001), as
well as for fasting glucose, impaired fast-
ing glucose, and hypertension.
In the top VAT tertile, absolute risk
factor prevalence was high and increased
signiﬁcantly with increasing SAT for sev-
eral risk factors. For example, linear
trends for rates of metabolic syndrome
were signiﬁcant for both women (51.2%
in SAT tertile 1 vs. 65.1% in SAT tertile 3,
P  0.02) and men (55.6% in SAT tertile
1 vs. 73.0% in SAT tertile 3, P  0.001).
However, the pattern of increase in risk
factor prevalence across SAT tertiles
present among the bottom two VAT ter-
tiles was notably absent among both men
and women in the highest VAT tertile for
low HDL and among men for fasting glu-
cose and impaired fasting glucose despite
large increases in BMI across SAT tertiles
(27.1 vs. 36.3 kg/m
2 for women and 28.1
vs. 35.7 kg/m
2 for men). In addition, prev-
alence rates of high triglycerides in men de-
creased signiﬁcantly with increasing SAT
(64.4% in SAT tertile 1 vs. 52.7% in SAT
tertile3,P0.03).Asimilartrendwasseen
in women, although it was not statistically
signiﬁcant(50.6%inSATtertile1vs.41.0%
in SAT tertile 3, P  0.10).
When the study sample was stratiﬁed
intoBMIcategories(normalweight,over-
weight, and obese), similar patterns were
observed (Fig. 1). The prevalence of all
risk factors markedly increased through
the BMI categories. Among those of nor-
mal weight, rates of high triglycerides in-
creased signiﬁcantly with SAT in both
women (5.2% in SAT tertile 1 vs. 14.4% in
SATtertile3,P0.002)andmen(8.4%in
SATtertile1vs.28.6%inSATtertile3,P
0.001). Among the overweight and obese,
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ides did not increase with SAT and de-
creased signiﬁcantly among obese women
(48.8% in SAT tertile 1 vs. 33.0% in SAT
tertile 3, P  0.02).
CONCLUSIONS
Principal ﬁndings
Cardiometabolic risk increases with in-
creasingvisceraladiposityandBMI.Among
those in the bottom two VAT tertiles, in-
creasing subcutaneous fat is generally asso-
ciated with increases in risk factor
prevalence. Among those in the highest
VAT tertile, however, increasing SAT is not
associated with uniform increases in risk
factors prevalence, despite signiﬁcant in-
creases in BMI, waist circumference SAT,
and VAT. Most striking, linear trends for
triglycerides actually decrease with increas-
ing SAT in the top VAT tertile, suggesting
that subcutaneous fat may be associated
with beneﬁcial effects on triglyceride levels
in those with the most visceral fat.
In the context of the current
literature
Although total adiposity is strongly asso-
ciated with metabolic and cardiovascular
risk, it is becoming increasingly clear that
differentfatcompartmentscontributedif-
ferentially to these risks. Abdominal vis-
ceral fat is a stronger correlate of
cardiovascular disease risk than BMI,
waist circumference, or abdominal sub-
cutaneous fat (5,6). Central obesity, in
which fat mass is predominantly intra-
abdominal, is more strongly associated
with insulin resistance, dyslipidemia, and
atherosclerosis than is peripheral obesity,
in which fat is predominantly gluteofem-
oral (1,15). Weight loss through diet and
exercise, which results in reductions in
visceral fat (16), is associated with im-
provements in insulin sensitivity (17),
blood pressure (18), serum lipids (19),
and inﬂammatory markers (20). Simi-
larly, loss of VAT by omentectomy leads
to decreases in glucose and insulin levels
(11), whereas loss of SAT by liposuction
does not always produce the same bene-
ﬁcial effects (12,13), suggesting that VAT
is more likely to be responsible for the
metabolic abnormalities associated with
obesity.
A few studies have suggested a possi-
ble beneﬁcial role for SAT, observing that
increased hip and thigh fat mass is asso-
ciated with lower glucose and lipid levels,
independent of abdominal fat (9). Pa-
tients with lipodystrophic loss of SAT
have an increased risk for insulin resis-
tance, diabetes, and dyslipidemia (21). In
mice, transplantation of subcutaneous fat
into visceral compartments leads to de-
creases in body weight and total fat mass
and improved glucose metabolism,
whereas transplantation of visceral fat
into either subcutaneous or visceral com-
partments results in no such improve-
ments. This suggests that subcutaneous
Figure 1—Age-adjusted levels of risk factors by tertile of SAT in normal-weight (A and D),
overweight (B and E), and obese (C and F) subjects. *P  0.05, **P  0.01, and ***P  0.001
for linear trend across tertiles. DM, diabetes; HTN, hypertension; IFG, impaired fasting glucose;
MetS, metabolic syndrome; TGs, triglycerides.
Subcutaneous adipose tissue and risk factors
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are metabolically beneﬁcial (14).
Our results conﬁrm that cardiometa-
bolic risk increases signiﬁcantly with in-
creases in VAT. The prevalence of many
risk factors, including hypertension and
the metabolic syndrome, also increases
with increasing SAT for all VAT and BMI
tertiles. Among those in the lower two-
thirds of the VAT distribution, more SAT
is also associated with increased risk of
most other risk factors examined, sug-
gesting that SAT is not protective in these
individuals. Among those with the most
VAT, however, increased SAT is associ-
ated with lower triglycerides, suggesting
that SAT may be associated with beneﬁ-
cial effects on triglyceride levels in the
obese.
Mechanisms
The ectopic fat hypothesis suggests that a
hallmark of obesity is fat deposition in
liver, skeletal muscle, and pancreatic
-cells resulting from insufﬁcient adipo-
cyte growth and differentiation in the set-
ting of nutritional excess (22). Such
ectopic fat stores are theorized to affect
tissue and organ function by physical
compression, the secretion of various lo-
cally acting substances, and cell dysfunc-
tion or cell death of nonadipose cells, a
phenomenon known as lipotoxicity (7).
In line with this theory, SAT represents a
proper expansion of nonpathogenic adi-
pocytes and therefore may be considered
aprotectivefatdepot(22).Improvements
in insulin sensitivity with thiazolidinedi-
one treatment, which increases subcuta-
neous fat stores, are suggestive of a
protective effect of SAT (10). Our results
are consistent with a potential protective
role for SAT in the case of triglycerides
among the obese.
Anotherpossibleexplanationforobe-
sity-related cardiometabolic disease is the
portal vein hypothesis, which proposes
that increased visceral fat leads to higher
free fatty acid concentrations in the portal
vein, increased systemic fatty acid ﬂux,
and increased hepatic lipase activity,
whichremoveslipidsfromLDLandHDL,
and may lead to dyslipidemia (23). Al-
though our results do not contradict the
detrimental effects of VAT proposed by
theportalveinhypothesis(theprevalence
of all risk factors increased with VAT ter-
tile in our sample), they do support the
notion that such a theory is, at best, in-
complete because it does not explain ei-
ther the detrimental or the beneﬁcial
effects of SAT, which does not drain
through the portal vein, on cardiometa-
bolic risk.
VAT and SAT differ not only in ana-
tomic location but also in cytokine secre-
tion proﬁle. SAT releases 2–3 times more
leptin than VAT (24), whereas VAT se-
cretes more adiponectin, interleukin-6,
interleukin-8, plasminogen activator in-
hibitor 1, and angiotensin than does SAT
(23). Although the relationships be-
tween VAT and SAT secretion proﬁles
and cardiometabolic pathogenesis are,
Figure 1—Continued.
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crine and perhaps endocrine factors
contribute to the differential effects of
VAT and SAT.
It is important to note that our results
suggest a possible protective effect of SAT
only among those in the highest tertile of
VAT. Indeed, in the lower VAT tertiles,
increasing SAT is associated only with in-
creases in risk factor prevalence. One ex-
planationforthisdifferenceisthatthereis
a relatively larger increase in VAT in the
lower tertiles and that SAT is simply a
markerforincreasedVATinthesegroups.
SAT by itself may not be deleterious or
beneﬁcial in the absence of the positive
energy balance of obesity. Accordingly,
SAT may only be protective in obese in-
dividualsbecausetheseindividualsareal-
ready in positive energy balance and SAT
provides a nonpathological energy stor-
age depot. It is also important to note that
the lack of increase in the prevalence of
riskfactorssuchaslowLDLandimpaired
fasting glucose with increasing SAT
among the obese may be due to a thresh-
old effect, whereby risk factor prevalence
is already so high that increasing SAT is
not associated with further increases in
prevalence.
Strengths and limitations
Compared with previous work on subcu-
taneous fat and cardiometabolic risk, the
strengths of the present study include a
largesamplesizewithawiderangeofBMI
and age, thereby reducing the likelihood
of ascertainment bias in the results. In ad-
dition, the study beneﬁts from the quan-
tiﬁcation of fat volumes from CT scans
rather than a single-slice measurement of
fat area. A major limitation of the study is
its lack of data on subcutaneous fat stores
aside from the abdomen; therefore, we
cannot generalize our ﬁndings to glu-
teofemoral fat. Further, we are unable to
separate deep versus superﬁcial SAT in
the abdomen. It may be that superﬁcial
SAT is less pathogenic than deep SAT
(25). In addition, analysis by VAT and
SAT tertiles increases the number of sta-
tistical tests performed, increasing the
likelihood of false-positive results at the
P  0.05 signiﬁcance level. Other limita-
tionsincludethecross-sectionalstudyde-
sign, which precludes inferences of
causality, and the lack of ethnic diversity,
which may limit generalizability to non-
white groups.
In summary, whereas abdominal ad-
iposity is associated with a higher abso-
lute risk of metabolic and cardiovascular
disease, subcutaneous abdominal fat is
notassociatedwithalinearincreaseinthe
prevalence of all risk factors among the
obese. Indeed, in the case of high triglyc-
erides, SAT may actually be a protective
fat depot in obese individuals.
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